{"id":4903,"date":"2019-11-13T18:54:01","date_gmt":"2019-11-13T13:24:01","guid":{"rendered":"https:\/\/triumphias.com\/blog\/?p=4903"},"modified":"2019-11-13T18:54:01","modified_gmt":"2019-11-13T13:24:01","slug":"cancer-treatment-receives-a-boost-in-india","status":"publish","type":"post","link":"https:\/\/triumphias.com\/blog\/cancer-treatment-receives-a-boost-in-india\/","title":{"rendered":"Cancer treatment receives a boost in India"},"content":{"rendered":"

Relevance: Mains: G.S paper III:\u00a0Science and Technology- developments and their applications and effects in everyday life\u00a0<\/strong><\/p>\n

A path-breaking cancer-treating device, developed in India, by an Indian scientist at the Bengaluru-based R&D facility of an American company, has just received approval from the US Food and Drugs Administration\u2019s (FDA) Center for Devices and Radiological Health, under the Breakthrough Device Program.<\/p>\n

The machine provides non-invasive tissue engineering that can help treat solid tumours of the breast, liver and pancreas, and is also useful in pain relief and palliative care.<\/p>\n

Research by Dr Rajah Vijay Kumar, at the Bengaluru-based Scalene Center for Advanced Research and Development, led to the invention of the Cytotron, a device that is based on quantum magnetic resonance therapy (QMRT).<\/p>\n

The body\u2019s tumour suppression mechanism is reactivated non-invasively by QMRT by targeting calibrated doses of radio- or sub-radio frequency, non-ionising, non-thermal electromagnetic waves at the tumour site.<\/p>\n

This triggers the production of new tumour suppressing nucleoproteins that lead to apopstosis (programmed cell death).<\/p>\n

Cytotron is likely to be of immense benefit in other solid tumours such as adult and pediatric brain tumours, lung cancer and many other life-limiting diseases\u2014the fact that it is lined up for application for Breakthrough Device designation for these cancer types suggests this.<\/p>\n

The US FDA\u2019s Breakthrough Device Program was intended to expedite access to new, life-saving medical devices for patients with life-threatening diseases.<\/p>\n

Under the programme, the US FDA guides the development of a product to the extent that it eases pre-market approval while meeting all the norms, and the product is accorded priority in the approval process.<\/p>\n

Cytotron has been demonstrated to be a unique, non-invasive cancer-treatment device that can target both primary and metastatic cancers simultaneously\u2014thereby meeting a key criterion for being designated as a \u201cBreakthrough Device\u201d.<\/p>\n

Indeed, Cytotron got the CE mark (the certification required for marketing of such products in the European Economic Area) in 2012 for the whole-body nine axes system that is used in tissue regeneration in osteoarthritis and other musculo skeletal disorders.<\/p>\n

Apart from this, Cytotron\u2019s technology is also indicated for regrowing cartilage, and treatment of spinal dysplasia and sports injuries.<\/p>\n

The invention could mean a new lease of life or vastly improved quality of living at the end-stage for millions of cancer patients around the world.<\/p>\n

As per the International Agency for Research on Cancer, in 2018, nearly 2.1 million cases of breast cancer, half a million cases of pancreatic cancer and over 800,000 liver cancer cases were detected.<\/p>\n

The ramifications of the technology are significant for India too\u2014of every two women newly diagnosed with breast cancer, one dies of the disease.<\/p>\n

With cancer being a major cause of morbidity and mortality in India\u2014the burden has more than doubled over the past two-and-half decades\u2014innovative solutions like Cytotron could prove a manna.<\/p>\n

The India connection underscores the R&D potential, with the right capital support, that country can tap into.<\/p>\n","protected":false},"excerpt":{"rendered":"

Relevance: Mains: G.S paper III:\u00a0Science and Technology- developments and their applications and effects in everyday life\u00a0 A path-breaking cancer-treating device,<\/p>\n","protected":false},"author":1,"featured_media":3528,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[123,42,69],"tags":[392],"class_list":["post-4903","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-current-affairs","category-general-studies-iii-technology-economic-development-bio-diversity-environment-security-and-disaster-management","category-science-and-technology","tag-union-public-service-commission-upsc"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/posts\/4903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/comments?post=4903"}],"version-history":[{"count":1,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/posts\/4903\/revisions"}],"predecessor-version":[{"id":4904,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/posts\/4903\/revisions\/4904"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/media\/3528"}],"wp:attachment":[{"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/media?parent=4903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/categories?post=4903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/triumphias.com\/blog\/wp-json\/wp\/v2\/tags?post=4903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}